NO20080434L - Luftveisadministrering av vevsfaktor veiinhibitorer i inflammatoriske tilstander som pavirker luftveien - Google Patents

Luftveisadministrering av vevsfaktor veiinhibitorer i inflammatoriske tilstander som pavirker luftveien

Info

Publication number
NO20080434L
NO20080434L NO20080434A NO20080434A NO20080434L NO 20080434 L NO20080434 L NO 20080434L NO 20080434 A NO20080434 A NO 20080434A NO 20080434 A NO20080434 A NO 20080434A NO 20080434 L NO20080434 L NO 20080434L
Authority
NO
Norway
Prior art keywords
inhibitors
respiratory tract
tissue factor
inflammatory conditions
conditions affecting
Prior art date
Application number
NO20080434A
Other languages
English (en)
Inventor
Lars Otto Uttenthal
Original Assignee
Drugrecure Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drugrecure Aps filed Critical Drugrecure Aps
Publication of NO20080434L publication Critical patent/NO20080434L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Den foreliggende oppfinnelse tilveiebringer fremgangsmåter for lokal behandling av akutt og kronisk ekstravaskulær, pulmonal fibrindeponering og/eller å redusere uønskede virkninger assosiert med systemisk administrering av naturlige antikoagulanter til et individ via luftveisadministrering til individet ved intratrakeale, intrabronkeale eller intraalveolære ruter av naturlige antikoagulanter eller biologisk aktive derivater derav.
NO20080434A 2005-06-24 2008-01-23 Luftveisadministrering av vevsfaktor veiinhibitorer i inflammatoriske tilstander som pavirker luftveien NO20080434L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69396805P 2005-06-24 2005-06-24
PCT/IB2006/002602 WO2006136962A2 (en) 2005-06-24 2006-06-23 Airway administration of tissue factor pathway inhibitor in inflammatory conditons affecting the respiratory tract

Publications (1)

Publication Number Publication Date
NO20080434L true NO20080434L (no) 2008-03-17

Family

ID=37570814

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20080433A NO20080433L (no) 2005-06-24 2008-01-23 Luftveisadministrering av aktivt protein C i inflammatoriske tilstander som pavirker luftveiene
NO20080434A NO20080434L (no) 2005-06-24 2008-01-23 Luftveisadministrering av vevsfaktor veiinhibitorer i inflammatoriske tilstander som pavirker luftveien

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20080433A NO20080433L (no) 2005-06-24 2008-01-23 Luftveisadministrering av aktivt protein C i inflammatoriske tilstander som pavirker luftveiene

Country Status (15)

Country Link
US (3) US8088728B2 (no)
EP (3) EP1898945B1 (no)
JP (3) JP2008543925A (no)
KR (2) KR20080074085A (no)
CN (2) CN101262879B (no)
AU (2) AU2006273696B2 (no)
BR (2) BRPI0613137A2 (no)
CA (2) CA2612646C (no)
DK (3) DK1898945T3 (no)
HK (1) HK1114567A1 (no)
IL (2) IL188220A0 (no)
NO (2) NO20080433L (no)
RU (2) RU2496516C2 (no)
WO (3) WO2006136963A2 (no)
ZA (2) ZA200800255B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008071197A1 (en) * 2006-12-11 2008-06-19 Drugrecure Aps Methods for treating cystic fibrosis or pneumonia with bacterial infection via pulmonary administration of fosfomycin
JP6273272B2 (ja) 2012-07-04 2018-01-31 ジージー バイオテック エルエルシー 炎症性皮膚障害の治療
PL3137102T3 (pl) 2014-04-16 2022-02-07 Zz Biotech Llc Apc do stosowania w leczeniu nieprawidłowego bliznowacenia skóry
US20190269765A1 (en) * 2016-09-13 2019-09-05 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5106833A (en) 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
US5378614A (en) 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
SE9200541D0 (sv) * 1992-02-24 1992-02-24 Kabi Pharmacia Ab New usee of omega-3-fatty acids
US5212091A (en) 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
AU730133B2 (en) * 1996-11-08 2001-02-22 Oklahoma Medical Research Foundation Modified protein C and methods of use thereof
US6497877B1 (en) * 1997-01-29 2002-12-24 University Technology Corporation Plasminogen activator as an anti-inflammatory agent
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6049577A (en) * 1998-05-28 2000-04-11 Glenayre Electronics, Inc. Header synchronization detector
AR023819A1 (es) * 1999-05-03 2002-09-04 Astrazeneca Ab FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
JP4848092B2 (ja) * 2000-02-01 2011-12-28 石原産業株式会社 ジアミノトリフルオロメチルピリジン誘導体を含有する肺不全の治療剤又は予防剤
ES2234807T3 (es) * 2000-02-02 2005-07-01 Eli Lilly And Company Derivados de proteina c.
DK1257295T3 (da) * 2000-02-11 2009-08-10 Bayer Healthcare Llc Faktor VII eller VIIA-lignende molekyler
US6933367B2 (en) * 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
RU2003134701A (ru) * 2001-05-02 2005-03-27 Ново Нордиск А/С (DK) Модифицированный fvii при лечении ards
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
BR0213292A (pt) * 2001-10-15 2006-05-23 Chiron Corp tratamento de pneumonia severa por administração de inibidor da via de fator tecidual (tfpi)
JP4229840B2 (ja) * 2002-02-08 2009-02-25 エスケー エナジー 株式会社 ヒーターチューブの洗浄のための洗浄剤および方法
WO2003090682A2 (en) * 2002-04-25 2003-11-06 The Scripps Research Institute Treatment and prevention of pulmonary conditions
ATE424215T1 (de) * 2003-01-08 2009-03-15 Novartis Vaccines & Diagnostic Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
JPWO2004087148A1 (ja) * 2003-03-31 2006-06-29 協和醗酵工業株式会社 肺疾患の治療および／または予防剤
WO2005042011A1 (en) * 2003-11-04 2005-05-12 Novo Nordisk A/S Pharmaceutical composition comprising a protein c polypeptide and a blood glucose regulator
MX2007002903A (es) * 2004-09-10 2007-07-11 Pharmaorigin Aps Metodos para el tratamiento de hemoptisis o hemorragias traqueales, bronquiales o alveolares, locales.
US8563511B2 (en) 2004-10-06 2013-10-22 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway

Also Published As

Publication number Publication date
RU2496516C2 (ru) 2013-10-27
CA2612646A1 (en) 2006-12-28
NO20080433L (no) 2008-03-19
AU2006260599A1 (en) 2006-12-28
CN101262880A (zh) 2008-09-10
US20100279925A1 (en) 2010-11-04
EP1906994B1 (en) 2014-04-23
WO2006136963A3 (en) 2007-07-12
EP1896059A2 (en) 2008-03-12
AU2006273696A1 (en) 2007-02-01
JP2008543926A (ja) 2008-12-04
JP2013151510A (ja) 2013-08-08
DK1896059T3 (da) 2013-04-08
CA2612646C (en) 2015-11-24
CN101262879A (zh) 2008-09-10
DK1898945T3 (da) 2013-03-25
DK1906994T3 (da) 2014-07-21
WO2007012976A2 (en) 2007-02-01
WO2006136963A2 (en) 2006-12-28
AU2006273696B2 (en) 2012-08-30
BRPI0613137A2 (pt) 2010-12-21
BRPI0611710A2 (pt) 2011-12-20
EP1896059B1 (en) 2012-12-19
RU2008102655A (ru) 2009-07-27
EP1898945B1 (en) 2012-12-19
IL188220A0 (en) 2008-03-20
RU2008102656A (ru) 2009-07-27
ZA200800255B (en) 2009-04-29
US20100297099A1 (en) 2010-11-25
US20100160218A1 (en) 2010-06-24
RU2496515C2 (ru) 2013-10-27
JP2008543925A (ja) 2008-12-04
EP1906994A2 (en) 2008-04-09
KR20080071116A (ko) 2008-08-01
US8088728B2 (en) 2012-01-03
ZA200800251B (en) 2009-04-29
CN101262879B (zh) 2013-04-10
CA2612597C (en) 2015-03-31
WO2006136962A2 (en) 2006-12-28
EP1898945A2 (en) 2008-03-19
WO2006136962A3 (en) 2007-07-12
KR20080074085A (ko) 2008-08-12
CA2612597A1 (en) 2007-02-01
WO2007012976A3 (en) 2007-07-12
HK1114567A1 (en) 2008-11-07
IL188221A0 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
Butterfield The Power of Anacrusis
NO20072466L (no) Fremgangsmate for a forhindre og behandle strukturendring i luftveier og pulmonal inflammasjon ved a anvende A2B-adenosinreseptorantagonister
NO20065232L (no) 8-(2-hydroksyfenoksy)oktyldietanolamin og salter derav for avlevering av aktive forbindelser
WO2006130873A3 (en) Methods and devices for maintaining surgically created channels in a body organ
ATE516285T1 (de) Dihydropyridinonderivate
DK1718336T3 (da) Ny kombination af anticholinergikum og beta-mimetika til behandling af luftvejssygdomme
NO20081354L (no) Dobbelt variabelt domeneimmunoglobin samt fremgangsmater derav
NO20080434L (no) Luftveisadministrering av vevsfaktor veiinhibitorer i inflammatoriske tilstander som pavirker luftveien
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
WO2008069972A3 (en) Systems for effecting cessation of tobacco use
WO2007091266A3 (en) Alpha-i antitrypsin for treating exacerbation episodes of pulmonary diseases
DK2098248T3 (da) Kombination af anticholinergika, glucocorticoider og beta2-agonister til behandling af inflammatoriske sygdomme
NO20083658L (no) Cyanoisokinolinforbindelser som stabiliserer hypoksi induserbar faktor(HIF)
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
WO2006130821A3 (en) Methods and devices for maintaining surgically created channels in a body organ
MX2011008799A (es) Polipeptidos, dominios variables de anticuerpos, y antagonistas anti-tnfr1 mejorados.
NO20070987L (no) Polysulfaterte glykosider og salter av disse.
NO20082434L (no) Materialer og fremgangsmater for behandling av kroniske fibrotiske sykdommer
NO20091509L (no) Substituerte tetrahydropyrrolopyrazinforbindelser med affinitet KCNQ2/3 K+ kanal og anvendelse derav i medikamenter
EP3750554A3 (en) Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
EA200970883A1 (ru) Индолкарбоксамиды как ингибиторы ikk2
ATE525394T1 (de) Peptide mit verbesserten eigenschaften mit der biologischen wirkung eines vasoaktiven intestinalen peptids (vip) und ihre verwendung zur behandlung von lungenerkrankung
NO20073680L (no) Fremgangsmate for a analysere data som har felles og saerskilte egenskaper
WO2008039941A3 (en) Scgb3a2 as a growth factor and anti-apoptotic agent
SE0401631D0 (sv) New Composition